Modalis Therapeutics Corporation (TYO:4883)

Market Cap	3.30B -45.0%
Revenue (ttm)	n/a
Net Income	-2.04B
EPS	-23.61
Shares Out	106.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	202,600
Open	31.00
Previous Close	31.00
Day's Range	31.00 - 32.00
52-Week Range	29.00 - 83.00
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Modalis Therapeutics

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorpor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 17
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4883

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 6, 2026

Data Sources Report a data error